Kisspeptin and gonadorelin both drive the reproductive hormone axis, but at different levels of the chain. Kisspeptin sits upstream — it's the "master switch" that tells GnRH neurons to fire. Gonadorelin is GnRH, the next step down, which then signals the pituitary. Gonadorelin is an established clinical agent; kisspeptin is an exciting investigational frontier.
At a glance
| Kisspeptin | Gonadorelin | |
|---|---|---|
| Role in the axis | Upstream 'master switch' that triggers GnRH | GnRH itself (next step down) |
| Acts on | GnRH neurons | Pituitary GnRH receptors |
| Status | Investigational (research) | Compounded / diagnostic use |
| Studied for | Fertility, low sexual desire, diagnostics | Fertility, pituitary testing |
| Maturity | Active research frontier | Long-established |
The bottom line
Bottom line: Think of kisspeptin as the switch above the switch. It triggers the GnRH neurons that gonadorelin (GnRH) embodies. Kisspeptin's appeal is that working a level higher may offer more physiological control — a reason it's an active research target for fertility and desire — but it remains investigational, while gonadorelin is already used clinically.
Frequently asked questions
What is the difference between kisspeptin and gonadorelin?
Kisspeptin acts upstream as a 'master switch' that triggers the GnRH neurons, while gonadorelin is GnRH itself, the next signal down that acts on the pituitary. Kisspeptin is investigational; gonadorelin is used clinically.
Why is kisspeptin considered a 'master switch'?
Kisspeptin sits above GnRH in the reproductive hierarchy — it tells GnRH neurons when to fire. Because it controls the controller, it's studied as a potentially more physiological way to influence fertility and sexual desire.
Is kisspeptin approved?
No. Kisspeptin is an investigational research compound. Gonadorelin (GnRH) is an established agent, typically compounded, used in fertility and diagnostic settings.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Mills EG, Thurston L, Dhillo WS, et al. Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open. 2023. Peer-reviewed study
- Thurston L, Hunjan T, Ertl N, et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open. 2022. Peer-reviewed study
- Xie Q, Kang Y, Zhang C, et al. The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction. Front Endocrinol (Lausanne). 2022. Peer-reviewed study
- Navarro VM. Metabolic regulation of kisspeptin - the link between energy balance and reproduction. Nat Rev Endocrinol. 2020. Peer-reviewed study
- Izzi-Engbeaya C, Hill TG, Bowe JE. Kisspeptin and Glucose Homeostasis. Semin Reprod Med. 2019. Peer-reviewed study
- Tsoutsouki J, Patel B, Comninos AN, et al. Kisspeptin in the Prediction of Pregnancy Complications. Front Endocrinol (Lausanne). 2022. Peer-reviewed study
- Loucopoulos A, Ferin M, Vande Wiele RL, et al. Pulsatile administration of gonadotropin-releasing hormone for induction of ovulation. Am J Obstet Gynecol. 1984. Peer-reviewed study
- Delemarre-van de Waal HA. Application of gonadotropin-releasing hormone in hypogonadotropic hypogonadism: diagnostic and therapeutic aspects. Eur J Endocrinol. 2004. Peer-reviewed study
- Hashimoto T, Miyai K. Gonadorelin and erythropoiesis. Arch Intern Med. 1981. Peer-reviewed study
- Torrini F, Scarano S, Palladino P, et al. Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin. J Pharm Biomed Anal. 2023. Peer-reviewed study
- Gonadorelin--synthetic LH-RH. Med Lett Drugs Ther. 1983. Peer-reviewed study
- Bouchard P. [Gonadorelin antagonists: present and future ]. Rev Prat. 2005. Peer-reviewed study